Iranian
Biomedical Journal
Volume 28, Issue 5 And 6 (9-2024)
IBJ 2024, 28(5 And 6): 273-281 |
Back to browse issues page
Ethics code: IR.PII.REC.1398.045
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Doroud D, Eftekhari Z, Daneshi M, Gheibi P, Jabbari N, Khatami M et al . Development of a Monocyte Activation Test for Evaluating Recombinant Hepatitis B Vaccine: A Novel Approach for Pyrogen Assessment. IBJ 2024; 28 (5 and 6) :273-281
URL: http://ibj.pasteur.ac.ir/article-1-4100-en.html
URL: http://ibj.pasteur.ac.ir/article-1-4100-en.html
Delaram Doroud 
, Zohre Eftekhari * , Mojtaba Daneshi , Parisa Gheibi , Nazzanin Jabbari , Maryam Khatami , Marzieh Hosseini
, Zohre Eftekhari * , Mojtaba Daneshi , Parisa Gheibi , Nazzanin Jabbari , Maryam Khatami , Marzieh Hosseini
Abstract:
Background: Injectable products, particularly human vaccines, must be free from fever-inducing agents and thoroughly tested for pyrogens as part of a quality control. Consequently, manufacturing facilities are required to conduct appropriate pyrogen tests per pharmacopeial standards. This study aimed to evaluate the reliability of the MAT in quantifying pyrogenic content in the recombinant hepatitis B vaccine.
Methods: We assessed pyrogen activity in the API, formulated vaccine, and aluminum hydroxide by comparing the LAL, RPT, and MAT, measuring activity in RPU as per the European Pharmacopeia. Monocytes from healthy donors were isolated and identified via flow cytometry to measure the CD14+ marker frequency.
Results: The study found that the pyrogenic concentration of LTA in the MAT was 50,000 ng/mL (5.19 EEU/mL). In contrast, the same concentration in the RPT was deemed non-pyrogenic based on rectal temperature assessments. The MAT showed sensitivity to the API and adjuvant, with a detection limit of 2.5 EU/mL for IL-6, outperforming the RPT, which had a detection limit of 5 EU/mL.
Conclusion: A strong IL-6 response to both LPS and LTA stimulation was observed, indicating that IL-6 could serve as a valuable marker for pyrogen testing. The MAT appears to be an effective alternative to the RPT for assessing pyrogenicity, demonstrating commendable consistency and accuracy across various testing systems allowed by the Ph. Eur. General MAT Chapter, especially given the RPT's limitations in controlling pyrogenicity in injectable products.
Methods: We assessed pyrogen activity in the API, formulated vaccine, and aluminum hydroxide by comparing the LAL, RPT, and MAT, measuring activity in RPU as per the European Pharmacopeia. Monocytes from healthy donors were isolated and identified via flow cytometry to measure the CD14+ marker frequency.
Results: The study found that the pyrogenic concentration of LTA in the MAT was 50,000 ng/mL (5.19 EEU/mL). In contrast, the same concentration in the RPT was deemed non-pyrogenic based on rectal temperature assessments. The MAT showed sensitivity to the API and adjuvant, with a detection limit of 2.5 EU/mL for IL-6, outperforming the RPT, which had a detection limit of 5 EU/mL.
Conclusion: A strong IL-6 response to both LPS and LTA stimulation was observed, indicating that IL-6 could serve as a valuable marker for pyrogen testing. The MAT appears to be an effective alternative to the RPT for assessing pyrogenicity, demonstrating commendable consistency and accuracy across various testing systems allowed by the Ph. Eur. General MAT Chapter, especially given the RPT's limitations in controlling pyrogenicity in injectable products.
Type of Study: Full Length/Original Article |
Subject:
Pharmaceutical Biotechnology
References
1. Schindler S, Aulock SV, Daneshian M, Hartung T. Development, validation and applications of the monocyte activation test for pyrogens based on human whole blood. Altex. 2009;26(4):265-77. [DOI:10.14573/altex.2009.4.265]
2. Valentin JP, Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods. 2008;58(2):77-87. [DOI:10.1016/j.vascn.2008.05.007]
3. de Mattos KA, Navega ECA, Silva VF, Almeida AS, da Silva CC, Presgrave OAF, et al. Applicability of the monocyte activation test (MAT) in the quality control of the 17DD yellow fever vaccine. Altern Lab Anim. 2018;46(1):23-37. [DOI:10.1177/026119291804600107]
4. Valentini S, Santoro G, Baffetta F, Franceschi S, Paludi M, Brandini E, et al. Monocyte-activation test to reliably measure the pyrogenic content of a vaccine: An in vitro pyrogen test to overcome in vivo limitations. Vaccine. 2019;37(29):3754-60. [DOI:10.1016/j.vaccine.2018.10.082]
5. Wright WF, Auwaerter PG. Fever and fever of unknown origin: review, recent advances, and lingering dogma. Open Forum Infect Dis. 2020;7(5):ofaa132. [DOI:10.1093/ofid/ofaa132]
6. Gimenes I, Caldeira C, Presgrave OAF, de Moura WC, Boas MHSV. Assessment of pyrogenic response of lipoteichoic acid by the monocyte activation test and the rabbit pyrogen test. Regul Toxicol Pharmacol. 2015;73(1):356-60. [DOI:10.1016/j.yrtph.2015.07.025]
7. Franchi L, Warner N, Viani K, Nuñez G. Function of Nod‐like receptors in microbial recognition and host defense. Immunol Rev. 2009;227(1):106-28. [DOI:10.1111/j.1600-065X.2008.00734.x]
8. 8. Blechova R, Pivodova D. Limulus amoebocyte lysate (LAL) test-An alternative method for detection of bacterial endotoxins. Acta Vet Brno. 2001;70:291-6. [DOI:10.2754/avb200170030291]
9. Vipond C, Findlay L, Feavers I, Care R. Limitations of the rabbit pyrogen test for assessing meningococcal OMV based vaccines. Altex. 2016;33(1):47-53. [DOI:10.14573/altex.1509291]
10. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Elsevier Inc., 2014. p. 3697.
11. Nadukkandy P, Balachandran MK, Valappil MP. Assessment of inflammatory response on pyrogenic induction by in vitro and in vivo methods. Biointerface Res Appl Chem. 2022;12(6):7668-84. [DOI:10.33263/BRIAC126.76687684]
12. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Inves. 1998;101(2):311-20. [DOI:10.1172/JCI1368]
13. Molenaar-de Backer MWA, Gitz E, Dieker M, Doodeman P, Ten Brinke A. Performance of monocyte activation test supplemented with human serum compared to fetal bovine serum. Altex. 2021;38(2):307-15. [DOI:10.14573/altex.2008261]
14. Stoppelkamp S, Würschum N, Stang K, Löder J, Avci‐Adali M, Toliashvili L, et al. Speeding up pyrogenicity testing: Identification of suitable cell components and readout parameters for an accelerated monocyte activation test (MAT). Drug Test Anal. 2017;9(2):260-73. [DOI:10.1002/dta.1973]
15. Sheraba NS, Diab MR, Yassin AS, Amin MA, Zedan HH. A Validation Study of the Limulus Amebocyte Lysate Test As An End-Product Endotoxin Test for Polyvalent Horse Snake Antivenom. PDA J Pharm Sci Technol. 2019;73(6): Available from: [DOI:10.5731/pdajpst.2018.009522]
16. Stoddard MB, Pinto V, Keiser PB, Zollinger W. Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clin Vaccine Immunol. 2010;17(1):98-107. [DOI:10.1128/CVI.00342-09]
17. Studholme L, Sutherland J, Desai T, Hockley J, Care R, Nordgren IK, Vipond C, Group CS. Evaluation of the monocyte activation test for the safety testing of meningococcal B vaccine Bexsero: A collaborative study. Vaccine. 2019;37(29):3761-9. [DOI:10.1016/j.vaccine.2018.05.073]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |